Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Payables (2019 - 2025)

Harmony Biosciences Holdings' Payables history spans 7 years, with the latest figure at $17.7 million for Q4 2025.

  • For Q4 2025, Payables rose 28.73% year-over-year to $17.7 million; the TTM value through Dec 2025 reached $17.7 million, up 28.73%, while the annual FY2025 figure was $17.7 million, 28.73% up from the prior year.
  • Payables for Q4 2025 was $17.7 million at Harmony Biosciences Holdings, down from $26.3 million in the prior quarter.
  • Across five years, Payables topped out at $28.3 million in Q2 2025 and bottomed at $1.0 million in Q4 2021.
  • The 5-year median for Payables is $8.5 million (2022), against an average of $11.4 million.
  • The largest annual shift saw Payables plummeted 60.84% in 2021 before it surged 368.3% in 2023.
  • A 5-year view of Payables shows it stood at $1.0 million in 2021, then surged by 278.22% to $3.8 million in 2022, then soared by 368.3% to $17.7 million in 2023, then fell by 22.48% to $13.7 million in 2024, then grew by 28.73% to $17.7 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Payables are $17.7 million (Q4 2025), $26.3 million (Q3 2025), and $28.3 million (Q2 2025).